|8-K||current report||Dec 1, 2015||144.6 KB|
|CT ORDER||confidential treatment order||Nov 19, 2015||8.9 KB|
|10-Q||quarterly report||Nov 12, 2015||436.7 KB|
|8-K||current report||Nov 12, 2015||230.3 KB|
|4||clendeninn, neil james||Oct 30, 2015||152.3 KB|
|S-3||registration statement||Oct 29, 2015||772.7 KB|
|8-K||current report||Sep 24, 2015||115.6 KB|
|SC 13G/A||amended statement of beneficial ownership||Sep 9, 2015||25.5 KB|
|S-8||registration statement||Aug 25, 2015||59.1 KB|
|4||bencich, john||Aug 20, 2015||26.0 KB|
|10-Q||quarterly report||Aug 13, 2015||444.5 KB|
|8-K||current report||Aug 13, 2015||143.7 KB|
|8-K||current report||Jul 13, 2015||40.0 KB|
|4||jacobs, cindy||Jun 16, 2015||26.3 KB|
|4||cormack, scott daniel||Jun 16, 2015||26.3 KB|
|8-K||current report||May 22, 2015||37.4 KB|
|4||parker, h stewart||May 22, 2015||27.1 KB|
|4||mattingly, martin a||May 22, 2015||27.1 KB|
|4||goldstein, jack||May 22, 2015||27.0 KB|
|4||clendeninn, neil james||May 22, 2015||27.1 KB|
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2017 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.